- Home
- SFL vs DYN Comparison
SFL vs DYN Comparison
Compare SFL & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- DYN
- Stock Information
- Founded
- SFL 2003
- DYN 1984
- Country
- SFL Bermuda
- DYN United States
- Employees
- SFL N/A
- DYN N/A
- Industry
- SFL Marine Transportation
- DYN Medicinal Chemicals and Botanical Products
- Sector
- SFL Consumer Discretionary
- DYN Health Care
- Exchange
- SFL Nasdaq
- DYN Nasdaq
- Market Cap
- SFL 1.0B
- DYN 848.8M
- IPO Year
- SFL N/A
- DYN 2020
- Fundamental
- Price
- SFL $8.31
- DYN $11.41
- Analyst Decision
- SFL Strong Buy
- DYN Strong Buy
- Analyst Count
- SFL 2
- DYN 12
- Target Price
- SFL $14.50
- DYN $47.00
- AVG Volume (30 Days)
- SFL 931.3K
- DYN 2.9M
- Earning Date
- SFL 05-20-2025
- DYN 05-08-2025
- Dividend Yield
- SFL 13.03%
- DYN N/A
- EPS Growth
- SFL 52.99
- DYN N/A
- EPS
- SFL 1.01
- DYN N/A
- Revenue
- SFL $894,061,000.00
- DYN N/A
- Revenue This Year
- SFL N/A
- DYN N/A
- Revenue Next Year
- SFL $5.63
- DYN N/A
- P/E Ratio
- SFL $8.20
- DYN N/A
- Revenue Growth
- SFL 20.12
- DYN N/A
- 52 Week Low
- SFL $6.78
- DYN $6.36
- 52 Week High
- SFL $14.62
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- SFL 56.18
- DYN 55.69
- Support Level
- SFL $8.09
- DYN $9.17
- Resistance Level
- SFL $8.45
- DYN $12.47
- Average True Range (ATR)
- SFL 0.20
- DYN 0.96
- MACD
- SFL 0.07
- DYN 0.13
- Stochastic Oscillator
- SFL 82.05
- DYN 67.88
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.